The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells

British Journal of Cancer

Volumn 86, Issue 9, 2002, Pages 1479-1486

  Senaratne, S G ^a   Mansi, J L ^a   Colston, K W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Bisphosphonates; Breast cancer; Caspases; Cytochrome c; Ras

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CYTOCHROME C; DNA FRAGMENT; MEVALONIC ACID; RAS PROTEIN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRENYLATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TIME SERIES ANALYSIS; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL MEMBRANE; CYTOCHROME C GROUP; DIPHOSPHONATES; FEMALE; GENES, RAS; HUMANS; IMIDAZOLES; PROTEIN ISOPRENYLATION; RAS PROTEINS; TUMOR CELLS, CULTURED;

EID: 0037029682     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600297     Document Type: Article

References (39)

1. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
2. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
3. Current use of bisphosphonates in oncology
4. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
5. Biphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
6. Caspases, the executioners of apoptosis
7. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture
8. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation
9. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
10. Morphological, biochemical, and flow cytometric assays of apoptosis
11. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
12. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
13. Bisphosphonates induce breast cancer cell death in vitro
14. The association between a mutated fas gene and cyclooxygenase-2 expression in human breast cancer cell lines
15. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases
16. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases
17. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
18. Farnesyl transferase inhibitors - A novel therapy for breast cancer
19. Bcl-2 gene family and the regulation of programmed cell death
20. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells
21. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of Ras-Raf complexes
22. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates anapoptotic protease cascade
23. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
24. Caspases disrupt mitochondrial membrane barrier function
25. G protein? Subunits contain a 20-carbon isoprenoid
26. Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: A preferential suppression of Ras farnesylation
27. Cleaved caspase-3, caspase-7 and poly (ADP-ribose) polymerase are complementarily but differentially expressed in human medulloblastomas
28. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
29. Intravenous etidronate in the management of malignant hypercalcaemia
30. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
31. Bisphosphonates induce apoptosis in human breast cancer cell lines
32. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
33. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: A potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release
34. Farnesyl pyrophosphate synthase is the molecular target of nitrogen containing bisphosphonates
35. The role of geranylgeranylation in bone formation and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
36. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
37. Effects of new bisphosphonates acids on tumor-induced bone destruction in the rat
38. Actions of bisphosphonate on bone metastasis in animal models of breast cancer carcinoma
39. Apaf-1, a human protein homologous to C. elegance CED-4, participates in cytochrome c-dependent activation of caspase-3